Health Care

Analysts See $-0.70 EPS for Neos Therapeutics Inc (NEOS)

The business had revenue of $4.91 million during the quarter. It has outperformed by 28.95% the S&P500. About shares traded. Neos Therapeutics Inc (NASDAQ:NEOS) has risen 9.07% since November 8, 2016 and is uptrending. Therefore 86% are positive.

Neos Therapeutics, Inc is a pharmaceutical company. $18.33's average target is 72.11% above currents $10.65 stock price. Finally, Royal Bank Of Canada set a $12.00 target price on Neos Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, August 8th. JMP Securities initiated the stock with "Market Outperform" rating in Monday, August 17 report. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Zacks Investment Research downgraded Neos Therapeutics from a "buy" rating to a "sell" rating in a research report on Thursday, October 19th. Cowen and Company reaffirmed a "buy" rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. The stock has "Neutral" rating by UBS on Monday, March 20. The firm has "Outperform" rating by RBC Capital Markets given on Monday, August 17. As per Tuesday, August 8, the company rating was maintained by RBC Capital Markets. The stock has "Outperform" rating by Wells Fargo on Friday, February 19. On Thursday, September 14 the stock rating was maintained by RBC Capital Markets with "Buy". Schwab Charles Investment Management Inc. acquired a new position in Neos Therapeutics during the second quarter worth $200,000. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. BMO Capital Markets reiterated a "buy" rating and issued a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, September 20th. (CET) has risen 32.01% since November 8, 2016 and is uptrending. It has underperformed by 7.63% the S&P500. Neos Therapeutics, Inc. has a 1 year low of $4.85 and a 1 year high of $13.15. The company has market cap of $292.74 million. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. It now has negative earnings. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NEOS. Zuckerman Investment Group Llc, a Illinois-based fund reported 37,275 shares. Deerfield Management Co is the second biggest holder with 2 million shares now valued at 10.92 million whilst Presidio Partners has 2 million shares valued at 8.82 million. Acadian Asset Mgmt Ltd Liability Corp holds 0.34% or 1.03M shares in its portfolio. Dodge And Cox has invested 0.38% in Synopsys, Inc. The Virginia-based 1607 Capital Partners Llc has invested 0.37% in the stock. (NASDAQ:SNPS). American Century owns 281,475 shares.



Like this

Latest


09 November 2017
Q3 Earnings Miss Sends Kohl's Corporation Stock Falling
It was also a blow to KSS stock by coming in below Wall Street's earnings per share estimate of 72 cents for the quarter. Narrowing in a bit closer, the 5 month price index is 1.10313, the 3 month is 1.0331, and the 1 month is now 0.93904.

09 November 2017
Virginia GOP Rep. Bob Goodlatte Announces He Is Retiring
He was due to rotate out of his chairmanship of the House Judiciary Committee at the end of this term. The 65-year-old congressman will retire from the House of Representatives after 26 years in office.

09 November 2017
Virginia Tech shifts gears to defending the triple option
Other than those two runs, Georgia Tech gained 200 rushing yards, which Foster feels like was a pretty darn good defensive effort. As they do every week, Virginia Tech has had its scout team try to simulate Georgia Tech's offense for its first-team defense.

09 November 2017
The MSI Financial Services Inc Reduces Stake in General Mills Inc. (GIS)
Los Angeles Capital Mgmt & Equity invested in 0.17% or 488,866 shares. (NYSE:GIS). 155,264 were accumulated by Huntington Bancorp. Williams Jones & Associates LLC's holdings in General Mills were worth $8,957,000 at the end of the most recent reporting period.

09 November 2017
The Teachers Advisors LLC decreases its position in AvalonBay Communities Inc. (AVB)
BidaskClub lowered shares of AvalonBay Communities from a "buy" rating to a "hold" rating in a report on Tuesday, July 11th. It worsened, as 48 investors sold MA shares while 480 reduced holdings. 72 funds opened positions while 128 raised stakes.

09 November 2017
China's October Consumer Inflation Hits 9-Month High
However, CPI rose to an annual rate of 1.9% in October, up from 1.6% in September and higher than the forecast of 1.8%. Food prices fell 0.4% from a year earlier, declining for the ninth straight month, after dropping 1.4% in September.

09 November 2017
Lookout for Relative Strength Index - Celgene Corporation (NASDAQ: CELG)
The company's Average Earnings Estimate for the Current Fiscal quarter is $1.33, according to consensus of 22 analysts. CME Group Inc ., a U.S. based Company, belongs to Financial sector and Investment Brokerage - National industry.

09 November 2017
Brooks Automation, Inc. Earnings Ahead: Quick Glance
University Of Texas Investment Managment Co holds 4.33% of its portfolio in Bio-Path Holdings Inc for 3.83 million shares. The Firm operates through two divisions: Brooks Semiconductor Solutions Group and Brooks Life Science Systems.

09 November 2017
Sturgill Simpson stages own concert outside CMA Awards
Come on down and join me! Sturgill played songs right in front of the arena entrance, and streamed the performance on Facebook . He announced the appearance a short time before on Facebook "So excited to be playing the #cmaawards tonight!" he wrote.

09 November 2017
RLJ Lodging Trust (NYSE:RLJ) Sentiment Change Report
The investment professionals in our partner's database now have: 126.18 million shares, up from 120.83 million shares in 2017Q1. The real estate investment trust reported $0.69 EPS for the quarter, missing the Zacks' consensus estimate of $0.70 by $0.01.



Recommended